Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 22
Filter
Add more filters










Publication year range
1.
Behav Brain Res ; 415: 113518, 2021 10 11.
Article in English | MEDLINE | ID: mdl-34391798

ABSTRACT

Obesity is a complex disease that is the result of a number of different factors including genetic, environmental, and endocrine abnormalities. Given that monogenic forms of obesity are rare, it is important to identify other mechanisms that contribute to its etiology. Methyl-Cp-G binding protein 2 (MeCP2) is a neuroepigenetic factor that binds to methylated regions of DNA to influence transcription. Past studies demonstrate that disruption in MeCP2 function produces obesity in mice. Using a diet-induced obesity mouse model, we show that perinatal exposure to high fat diet significantly decreases MeCP2 protein expression in the hypothalamus of female mice, effects not seen when high fat diet is given to mice during adulthood. Moreover, these effects are seen specifically in a subregion of the hypothalamus known as the arcuate nucleus with females having decreased MeCP2 expression in rostral areas and males having decreased MeCP2 expression in intermediate regions of the arcuate nucleus. Interestingly, mice gain more weight when exposed to high fat diet during adulthood relative to mice exposed to high fat diet perinatally, suggesting that perhaps high fat diet exposure during adulthood may be affecting mechanisms independent of MeCP2 function. Collectively, our data demonstrate that there are developmentally sensitive periods in which MeCP2 expression is influenced by high fat diet exposure and this occurs in a sexually dimorphic manner.


Subject(s)
Diet, High-Fat , Hypothalamus/metabolism , Methyl-CpG-Binding Protein 2/metabolism , Obesity/metabolism , Age Factors , Animals , Animals, Newborn , Disease Models, Animal , Female , Male , Mice , Sex Characteristics
2.
Nat Neurosci ; 24(8): 1100-1109, 2021 08.
Article in English | MEDLINE | ID: mdl-34183865

ABSTRACT

The rapidly acting antidepressants ketamine and scopolamine exert behavioral effects that can last from several days to more than a week in some patients. The molecular mechanisms underlying the maintenance of these antidepressant effects are unknown. Here we show that methyl-CpG-binding protein 2 (MeCP2) phosphorylation at Ser421 (pMeCP2) is essential for the sustained, but not the rapid, antidepressant effects of ketamine and scopolamine in mice. Our results reveal that pMeCP2 is downstream of BDNF, a critical factor in ketamine and scopolamine antidepressant action. In addition, we show that pMeCP2 is required for the long-term regulation of synaptic strength after ketamine or scopolamine administration. These results demonstrate that pMeCP2 and associated synaptic plasticity are essential determinants of sustained antidepressant effects.


Subject(s)
Antidepressive Agents/pharmacology , Brain-Derived Neurotrophic Factor/metabolism , Brain/drug effects , Methyl-CpG-Binding Protein 2/metabolism , Neuronal Plasticity/drug effects , Animals , Brain/metabolism , Ketamine/pharmacology , Mice , Mice, Inbred C57BL , Mice, Knockout , Neuronal Plasticity/physiology , Phosphorylation , Scopolamine/pharmacology
3.
PLoS One ; 15(12): e0244793, 2020.
Article in English | MEDLINE | ID: mdl-33382813

ABSTRACT

Enhancer redundancy has been postulated to provide a buffer for gene expression against genetic and environmental perturbations. While work in Drosophila has identified functionally overlapping enhancers, work in mammalian models has been limited. Recently, we have identified two partially redundant enhancers, nPE1 and nPE2, that drive proopiomelanocortin gene expression in the hypothalamus. Here we demonstrate that deletion of nPE1 produces mild obesity while knockout of nPE2 has no discernible metabolic phenotypes. Additionally, we show that acute leptin administration has significant effects on nPE1 knockout mice, with food intake and body weight change significantly impacted by peripheral leptin treatment. nPE1 knockout mice became less responsive to leptin treatment over time as percent body weight change increased over 2 week exposure to peripheral leptin. Both Pomc and Agrp mRNA were not differentially affected by chronic leptin treatment however we did see a decrease in Pomc and Agrp mRNA in both nPE1 and nPE2 knockout calorie restricted mice as compared to calorie restricted PBS-treated WT mice. Collectively, these data suggest dynamic regulation of Pomc by nPE1 such that mice with nPE1 knockout become less responsive to the anorectic effects of leptin treatment over time. Our results also support our earlier findings in which nPE2 may only be critical in adult mice that lack nPE1, indicating that these neural enhancers work synergistically to influence metabolism.


Subject(s)
Appetite Depressants/pharmacology , Body Weight/drug effects , Eating/drug effects , Enhancer Elements, Genetic , Hypothalamus/drug effects , Leptin/pharmacology , Neurons/drug effects , Pro-Opiomelanocortin/genetics , Animals , Hypothalamus/metabolism , Male , Mice , Mice, Knockout , Neurons/metabolism
5.
PLoS One ; 12(8): e0183026, 2017.
Article in English | MEDLINE | ID: mdl-28813484

ABSTRACT

Rett syndrome (RTT), a leading cause of intellectual disability in girls, is predominantly caused by mutations in the X-linked gene MECP2. Disruption of Mecp2 in mice recapitulates major features of RTT, including neurobehavioral abnormalities, which can be reversed by re-expression of normal Mecp2. Thus, there is reason to believe that RTT could be amenable to therapeutic intervention throughout the lifespan of patients after the onset of symptoms. A common feature underlying neuropsychiatric disorders, including RTT, is altered synaptic function in the brain. Here, we show that Mecp2tm1.1Jae/y mice display lower presynaptic function as assessed by paired pulse ratio, as well as decreased long term potentiation (LTP) at hippocampal Schaffer-collateral-CA1 synapses. Treatment of Mecp2tm1.1Jae/y mice with D-cycloserine (DCS), an FDA-approved analog of the amino acid D-alanine with antibiotic and glycinergic activity, corrected the presynaptic but not LTP deficit without affecting deficient hippocampal BDNF levels. DCS treatment did, however, partially restore lower BDNF levels in the brain stem and striatum. Thus, treatment with DCS may mitigate the severity of some of the neurobehavioral symptoms experienced by patients with Rett syndrome.


Subject(s)
Cycloserine/pharmacology , Rett Syndrome/physiopathology , Synaptic Transmission/drug effects , Animals , Apnea , Brain Stem/metabolism , Brain Stem/physiopathology , Brain-Derived Neurotrophic Factor/metabolism , Corpus Striatum/metabolism , Corpus Striatum/physiopathology , Cycloserine/administration & dosage , Disease Models, Animal , Gait/drug effects , Hippocampus/drug effects , Hippocampus/physiopathology , Locomotion/drug effects , Male , Methyl-CpG-Binding Protein 2/genetics , Mice , Mice, Transgenic , Muscle Strength/drug effects , Rett Syndrome/drug therapy , Rett Syndrome/genetics , Rett Syndrome/metabolism , Tremor
6.
Neurobiol Learn Mem ; 135: 139-145, 2016 Nov.
Article in English | MEDLINE | ID: mdl-27545441

ABSTRACT

DNA methylation has been shown to impact certain forms of synaptic and behavioral plasticity that have been implicated in the development in psychiatric disorders. DNA methylation is catalyzed by DNA methyltransferase (DNMT) enzymes that continue to be expressed in postmitotic neurons in the forebrain. Using a conditional forebrain knockout of DNMT1 or DNMT3a we assessed the role of these DNMTs in anxiety and depressive-like behavior in mice using an array of behavioral testing paradigms. Forebrain deletion of DNMT1 had anxiolytic and antidepressant-like properties as assessed by elevated plus maze, novelty suppressed feeding, forced swim, and social interaction tests. DNMT3a knockout mice, by contrast, did not exhibit significant behavioral alterations in these tests. Given the putative role of altered DNA methylation patterns in the development of schizophrenia, we also assessed DNMT1 and DNMT3a knockout mice in a prepulse inhibition task and found an enhanced prepulse inhibition of startle in DNMT1 knockouts relative to wild type mice, with no change evident in DNMT3a knockout mice. Our data suggest that DNMT1 and DNMT3a are distinctly involved in affective behavior and that DNMT1 may ultimately represent a potential target for treatment of certain affective behavioral disorders.


Subject(s)
Anxiety , Behavior, Animal/physiology , DNA (Cytosine-5-)-Methyltransferase 1/physiology , DNA (Cytosine-5-)-Methyltransferases/physiology , Depression , Prepulse Inhibition , Prosencephalon/metabolism , Animals , Anxiety/genetics , Anxiety/physiopathology , DNA (Cytosine-5-)-Methyltransferase 1/genetics , DNA (Cytosine-5-)-Methyltransferases/genetics , DNA Methyltransferase 3A , Depression/genetics , Depression/physiopathology , Disease Models, Animal , Male , Mice , Mice, 129 Strain , Mice, Inbred BALB C , Mice, Inbred C57BL , Mice, Knockout , Prepulse Inhibition/genetics , Prepulse Inhibition/physiology
7.
Neurobiol Learn Mem ; 115: 30-7, 2014 Nov.
Article in English | MEDLINE | ID: mdl-24937014

ABSTRACT

Methylation of cytosine nucleotides is governed by DNA methyltransferases (DNMTs) that establish de novo DNA methylation patterns in early embryonic development (e.g., DNMT3a and DNMT3b) or maintain those patterns on hemimethylated DNA in dividing cells (e.g., DNMT1). DNMTs continue to be expressed at high levels in mature neurons, however their impact on neuronal function and behavior are unclear. To address this issue we examined DNMT1 and DNMT3a expression following associative learning. We also generated forebrain specific conditional Dnmt1 or Dnmt3a knockout mice and characterized them in learning and memory paradigms as well as for alterations in long-term potentiation (LTP) and synaptic plasticity. Here, we report that experience in an associative learning task impacts expression of Dnmt3a, but not Dnmt1, in brain areas that mediate learning of this task. We also found that Dnmt3a knockout mice, and not Dnmt1 knockouts have synaptic alterations as well as learning deficits on several associative and episodic memory tasks. These findings indicate that the de novo DNA methylating enzyme DNMT3a in postmitotic neurons is necessary for normal memory formation and its function cannot be substituted by the maintenance DNA methylating enzyme DNMT1.


Subject(s)
DNA (Cytosine-5-)-Methyltransferases/physiology , Learning/physiology , Memory/physiology , Animals , Conditioning, Classical/physiology , DNA Methyltransferase 3A , Hippocampus/physiology , Long-Term Potentiation/physiology , Memory, Episodic , Mice, Inbred BALB C , Mice, Inbred C57BL , Mice, Knockout , Real-Time Polymerase Chain Reaction , Repressor Proteins/physiology
8.
Neuropsychopharmacology ; 39(8): 1946-54, 2014 Jul.
Article in English | MEDLINE | ID: mdl-24549116

ABSTRACT

Methyl-CpG-binding protein 2 (MeCP2) is a ubiquitously expressed transcriptional regulator with functional importance in the central nervous system. Loss-of-function mutations in MECP2 results in the neurodevelopmental disorder, Rett syndrome, whereas increased expression levels are associated with the neurological disorder, MECP2 duplication syndrome. Previous characterization of a mouse line overexpressing Mecp2 demonstrated that this model recapitulated key behavioral features of MECP2 duplication syndrome with specific deficits in synaptic plasticity and neurotransmission. Alterations in excitation/inhibition balance have been suggested to underlie neurodevelopmental disorders with recent data suggesting that picrotoxin (PTX), a GABAA receptor antagonist, rescues certain behavioral and synaptic phenotypes in a mouse model of Down syndrome. We therefore examined whether a similar treatment regimen would impact the behavioral and synaptic phenotypes in a mouse model of MECP2 duplication syndrome. We report that chronic treatment with low doses of PTX ameliorates specific behavioral phenotypes, including motor coordination, episodic memory impairments, and synaptic plasticity deficits. These findings suggest that GABAA receptor antagonists may offer a possible therapeutic target for the treatment of MECP2 duplication syndrome.


Subject(s)
GABA-A Receptor Antagonists/therapeutic use , Mental Retardation, X-Linked/drug therapy , Neuronal Plasticity/drug effects , Picrotoxin/therapeutic use , Animals , Behavior, Animal/drug effects , Disease Models, Animal , Hippocampus/drug effects , Male , Methyl-CpG-Binding Protein 2/genetics , Mice , Mice, Inbred C57BL , Mice, Transgenic
9.
J Neurosci ; 33(15): 6401-11, 2013 Apr 10.
Article in English | MEDLINE | ID: mdl-23575838

ABSTRACT

Histone acetylation and deacetylation can be dynamically regulated in response to environmental stimuli and play important roles in learning and memory. Pharmacological inhibition of histone deacetylases (HDACs) improves performance in learning tasks; however, many of these classical agents are "pan-HDAC" inhibitors, and their use makes it difficult to determine the roles of specific HDACs in cognitive function. We took a genetic approach using mice lacking the class I HDACs, HDAC1 or HDAC2, in postmitotic forebrain neurons to investigate the specificity or functional redundancy of these HDACs in learning and synaptic plasticity. We show that selective knock-out of Hdac2 led to a robust acceleration of the extinction rate of conditioned fear responses and a conditioned taste aversion as well as enhanced performance in an attentional set-shifting task. Hdac2 knock-out had no impact on episodic memory or motor learning, suggesting that the effects are task-dependent, with the predominant impact of HDAC2 inhibition being an enhancement in an animal's ability to rapidly adapt its behavioral strategy as a result of changes in associative contingencies. Our results demonstrate that the loss of HDAC2 improves associative learning, with no effect in nonassociative learning tasks, suggesting a specific role for HDAC2 in particular types of learning. HDAC2 may be an intriguing target for cognitive and psychiatric disorders that are characterized by an inability to inhibit behavioral responsiveness to maladaptive or no longer relevant associations.


Subject(s)
Association Learning/physiology , Conditioning, Psychological/physiology , Extinction, Psychological/physiology , Histone Deacetylase 1/physiology , Histone Deacetylase 2/physiology , Memory, Short-Term/physiology , Animals , Brain/metabolism , Brain/physiology , Dendritic Spines/genetics , Hippocampus/physiology , Histone Deacetylase 1/genetics , Histone Deacetylase 1/metabolism , Histone Deacetylase 2/genetics , Histone Deacetylase 2/metabolism , Mice , Mice, Knockout , Motor Activity/physiology , Neuronal Plasticity/genetics , Neuronal Plasticity/physiology , Neurons/physiology , Rotarod Performance Test/methods
10.
Appetite ; 64: 81-8, 2013 May.
Article in English | MEDLINE | ID: mdl-23318656

ABSTRACT

Both chronic stress and antidepressant medications have been associated with changes in body weight. In the current study, we investigate mechanisms by which stress and antidepressants interact to affect meal patterns. A group of mice was subjected to the chronic social defeat stress model of major depression followed by fluoxetine treatment and was subsequently analyzed for food intake using metabolic cages. We report that chronic social defeat stress increases food intake by specifically increasing meal size, an effect that is reversed by fluoxetine treatment. In an attempt to gain mechanistic insight into changes in meal patterning induced by stress and fluoxetine, fasting serum samples were collected every 4h over a 24-h period, and acyl-ghrelin, leptin, and corticosterone levels were measured. Chronic stress induces a peak in acyl-ghrelin levels just prior to the onset of the dark phase, which is shifted in mice treated with fluoxetine. Taken together, these results indicate that stress increases food intake by decreasing satiation, and that fluoxetine can reverse stress-induced changes in meal patterns.


Subject(s)
Antidepressive Agents, Second-Generation/pharmacology , Eating , Energy Intake , Fluoxetine/therapeutic use , Meals , Obesity , Stress, Psychological/complications , Animals , Chronic Disease , Corticosterone/blood , Eating/drug effects , Energy Intake/drug effects , Fluoxetine/pharmacology , Ghrelin/blood , Leptin/blood , Meals/drug effects , Mice , Obesity/blood , Obesity/etiology , Obesity/prevention & control , Satiation/drug effects , Selective Serotonin Reuptake Inhibitors/pharmacology , Selective Serotonin Reuptake Inhibitors/therapeutic use , Social Environment
11.
Neuropsychopharmacology ; 38(1): 212-9, 2013 Jan.
Article in English | MEDLINE | ID: mdl-22781840

ABSTRACT

Methyl-CpG-binding protein 2 (MeCP2) is a transcriptional regulator of gene expression that is an important epigenetic factor in the maintenance and development of the central nervous system. The neurodevelopmental disorders Rett syndrome and MECP2 duplication syndrome arise from loss-of-function and gain-of-function alterations in MeCP2 expression, respectively. Several animal models have been developed to recapitulate the symptoms of Rett syndrome and MECP2 duplication syndrome. Cell morphology, neurotransmission, and cellular processes that support learning and memory are compromised as a result of MeCP2 loss- or gain-of-function. Interestingly, loss-of-MeCP2 function and MeCP2 overexpression trigger diametrically opposite changes in synaptic transmission. These findings indicate that the precise regulation of MeCP2 expression is a key requirement for the maintenance of synaptic and neuronal homeostasis and underscore its importance in central nervous system function. This review highlights the functional role of MeCP2 in the brain as a regulator of synaptic and neuronal plasticity as well as its etiological role in the development of Rett syndrome and MECP2 duplication syndrome.


Subject(s)
Methyl-CpG-Binding Protein 2/physiology , Neuronal Plasticity/physiology , Synapses/physiology , Synaptic Transmission/physiology , Animals , Humans , Rett Syndrome/genetics , Rett Syndrome/metabolism
12.
Behav Neurosci ; 126(4): 582-7, 2012 Aug.
Article in English | MEDLINE | ID: mdl-22845707

ABSTRACT

Physical exercise has mood-enhancing and antidepressant properties although the mechanisms underlying these effects are not known. The present experiment investigated the effects of prolonged access to a running wheel on electrical self-stimulation of the lateral hypothalamus (LHSS), a measure of hedonic state, in rats. Rats with continuous voluntary access to a running wheel for either 2 or 5 weeks exhibited dramatic leftward shifts in the effective current 50 (ECu50; current value that supports half of maximum responding) of their LHSS current-response functions compared to their baselines, indicating a decrease in reward threshold, whereas control rats current-response functions after 2 or 5 weeks were not significantly different from baseline. An inverse correlation existed between the change in ECu50 from baseline and the amount an animal had run in the day prior to LHSS testing, indicating that animals that exhibited higher levels of running showed a more robust decrease in LHSS threshold. We conclude that long-term voluntary exercise increases sensitivity to rewarding stimuli, which may contribute to its antidepressant properties.


Subject(s)
Conditioning, Operant/physiology , Hypothalamic Area, Lateral/physiology , Physical Conditioning, Animal , Reward , Running/physiology , Analysis of Variance , Animals , Behavior, Animal , Body Weight , Electric Stimulation/methods , Male , Random Allocation , Rats , Rats, Sprague-Dawley , Self Stimulation
13.
J Neurosci ; 32(9): 3109-17, 2012 Feb 29.
Article in English | MEDLINE | ID: mdl-22378884

ABSTRACT

Rett syndrome and MECP2 duplication syndrome are neurodevelopmental disorders that arise from loss-of-function and gain-of-function alterations in methyl-CpG binding protein 2 (MeCP2) expression, respectively. Although there have been studies examining MeCP2 loss of function in animal models, there is limited information on MeCP2 overexpression in animal models. Here, we characterize a mouse line with MeCP2 overexpression restricted to neurons (Tau-Mecp2). This MeCP2 overexpression line shows motor coordination deficits, heightened anxiety, and impairments in learning and memory that are accompanied by deficits in long-term potentiation and short-term synaptic plasticity. Whole-cell voltage-clamp recordings of cultured hippocampal neurons from Tau-Mecp2 mice reveal augmented frequency of miniature EPSCs with no change in miniature IPSCs, indicating that overexpression of MeCP2 selectively impacts excitatory synapse function. Moreover, we show that alterations in transcriptional repression mechanisms underlie the synaptic phenotypes in hippocampal neurons from the Tau-Mecp2 mice. These results demonstrate that the Tau-Mecp2 mouse line recapitulates many key phenotypes of MECP2 duplication syndrome and support the use of these mice to further study this devastating disorder.


Subject(s)
Disease Models, Animal , Gene Duplication/physiology , Gene Expression Regulation , Memory/physiology , Methyl-CpG-Binding Protein 2/biosynthesis , Synaptic Transmission/physiology , Animals , Learning/physiology , Male , Methyl-CpG-Binding Protein 2/genetics , Mice , Mice, Inbred C57BL , Mice, Transgenic , Rett Syndrome/genetics , Rett Syndrome/metabolism , Syndrome , tau Proteins/genetics
14.
Physiol Behav ; 106(2): 164-70, 2012 May 15.
Article in English | MEDLINE | ID: mdl-22326670

ABSTRACT

Sodium deficiency reliably produces a robust intake of saline in rats, which is associated with an increased preference for sodium solutions at hypertonic concentrations that would normally be avoided. The mechanisms underlying the shift to an increased preference for sodium in the deficient state are not well understood. The current experiments examined the role of opioids on changes of behavioral responses that are modified as a function of body sodium status by studying the intake of 0.3 M saline in a free access drinking test and by characterizing the changes in orofacial-related behaviors in response to intra-orally delivered 0.3 M NaCl. In intake tests, systemic treatment with morphine and naltrexone respectively, enhanced and attenuated intake of 0.3 M saline in sodium depleted rats. In taste reactivity tests systemic treatment with morphine significantly decreased negative responses to 0.3 M saline infusions in both sodium replete and sodium depleted rats. Systemically administered naltrexone significantly decreased positive hedonic responses to 0.3 M saline infusions only in sodium depleted rats. These results indicate that peripheral administration of opioid agonists and antagonists alter both hypertonic saline ingestion in a free access situation and taste reactivity responses to hypertonic saline under sodium replete and deplete conditions. The results indicate that endogenous opioids alter the processing of central information to affect hedonic mechanisms that influence behaviors related to sodium consumption and palatability.


Subject(s)
Appetite Regulation/physiology , Food Preferences/physiology , Hyponatremia/physiopathology , Opioid Peptides/physiology , Sodium Chloride/metabolism , Taste/physiology , Animals , Drinking/drug effects , Drinking/physiology , Food Preferences/drug effects , Furosemide/adverse effects , Hyponatremia/chemically induced , Male , Morphine/antagonists & inhibitors , Morphine/pharmacology , Naloxone/pharmacology , Rats , Rats, Sprague-Dawley , Saline Solution, Hypertonic/pharmacology , Sodium Chloride/pharmacology
15.
Nature ; 475(7354): 91-5, 2011 Jun 15.
Article in English | MEDLINE | ID: mdl-21677641

ABSTRACT

Clinical studies consistently demonstrate that a single sub-psychomimetic dose of ketamine, an ionotropic glutamatergic NMDAR (N-methyl-D-aspartate receptor) antagonist, produces fast-acting antidepressant responses in patients suffering from major depressive disorder, although the underlying mechanism is unclear. Depressed patients report the alleviation of major depressive disorder symptoms within two hours of a single, low-dose intravenous infusion of ketamine, with effects lasting up to two weeks, unlike traditional antidepressants (serotonin re-uptake inhibitors), which take weeks to reach efficacy. This delay is a major drawback to current therapies for major depressive disorder and faster-acting antidepressants are needed, particularly for suicide-risk patients. The ability of ketamine to produce rapidly acting, long-lasting antidepressant responses in depressed patients provides a unique opportunity to investigate underlying cellular mechanisms. Here we show that ketamine and other NMDAR antagonists produce fast-acting behavioural antidepressant-like effects in mouse models, and that these effects depend on the rapid synthesis of brain-derived neurotrophic factor. We find that the ketamine-mediated blockade of NMDAR at rest deactivates eukaryotic elongation factor 2 (eEF2) kinase (also called CaMKIII), resulting in reduced eEF2 phosphorylation and de-suppression of translation of brain-derived neurotrophic factor. Furthermore, we find that inhibitors of eEF2 kinase induce fast-acting behavioural antidepressant-like effects. Our findings indicate that the regulation of protein synthesis by spontaneous neurotransmission may serve as a viable therapeutic target for the development of fast-acting antidepressants.


Subject(s)
Antidepressive Agents/pharmacology , Ketamine/pharmacology , Receptors, N-Methyl-D-Aspartate/antagonists & inhibitors , Rest/physiology , Animals , Behavior, Animal/drug effects , Behavior, Animal/physiology , Brain-Derived Neurotrophic Factor/biosynthesis , Brain-Derived Neurotrophic Factor/deficiency , Brain-Derived Neurotrophic Factor/genetics , Brain-Derived Neurotrophic Factor/pharmacology , Depression/drug therapy , Disease Models, Animal , Dizocilpine Maleate/pharmacology , Elongation Factor 2 Kinase/metabolism , Gene Expression Regulation/drug effects , Mice , Mice, Inbred C57BL , Mice, Knockout , Phosphorylation/drug effects , Piperazines/pharmacology , Protein Biosynthesis/drug effects , Receptors, N-Methyl-D-Aspartate/metabolism , Synapses/drug effects , Synapses/metabolism , Synaptic Transmission/drug effects , Time Factors , Suicide Prevention
16.
Horm Behav ; 59(3): 364-8, 2011 Mar.
Article in English | MEDLINE | ID: mdl-20515694

ABSTRACT

Rett syndrome is a neurodevelopmental disorder that is a direct consequence of functional mutations in the methyl-CpG-binding protein-2 (MeCP2) gene, which has focused attention on epigenetic mechanisms in neurons. MeCP2 is widely believed to be a transcriptional repressor although it may have additional functions in the CNS. Genetic mouse models that compromise MeCP2 function demonstrate that homeostatic regulation of MeCP2 is necessary for normal CNS functioning. Recent work has also demonstrated that MeCP2 plays an important role in mediating synaptic transmission in the CNS in particular, spontaneous neurotransmission and short-term synaptic plasticity. This review will discuss the role of MeCP2 in CNS development and function, as well as a potential important role for MeCP2 and epigenetic processes involved in mediating transcriptional repression in Rett syndrome.


Subject(s)
Epigenesis, Genetic , Methyl-CpG-Binding Protein 2/metabolism , Rett Syndrome/metabolism , Animals , Disease Models, Animal , Methyl-CpG-Binding Protein 2/genetics , Mice , Mutation , Neurons/metabolism , Rett Syndrome/genetics , Synaptic Transmission/genetics
17.
Behav Neurosci ; 124(2): 211-24, 2010 Apr.
Article in English | MEDLINE | ID: mdl-20364881

ABSTRACT

Our laboratory has reported that manipulations that provoke a robust sodium appetite (e.g., sodium depletion, deoxycorticosterone acetate) decrease lateral hypothalamic self-stimulation (LHSS) reward if rats are denied access to hypertonic saline solutions. The following studies investigated the interaction between chronic sodium appetite and the renin-angiotensin-aldosterone system on LHSS reward. In Experiment 1, animals treated with the diuretic furosemide (20 mg/kg) when denied access to saline exhibited an increase in the current required to produce 50% of the maximum LHSS response rate (ECu50) 48 hr after extracellular volume depletion. Furosemide-depleted rats that were allowed to drink 0.3 M saline after depletion, or that were treated with the selective mineralocorticoid receptor (MR) antagonist spironolactone, which significantly reduced sodium appetite, did not show ECu50 changes. In Experiment 2 chronic intracerebroventricular administration of the selective MR antagonist RU 28318 (10 microg/microl/hr) prevented decreases in the ECu50 induced by deoxycorticosterone acetate-no salt treatment. We conclude that an unresolved sodium appetite will reduce responding for rewards and that experimental manipulations that reduce sodium appetite (e.g., access to saline or blockade of MR) decrease hedonic deficits.


Subject(s)
Hyponatremia/psychology , Hypothalamic Area, Lateral/drug effects , Mineralocorticoid Receptor Antagonists , Renin-Angiotensin System/drug effects , Reward , Self Stimulation/drug effects , Aldosterone/blood , Animals , Appetite/drug effects , Appetite/physiology , Captopril/pharmacology , Desoxycorticosterone/analogs & derivatives , Drug Interactions , Furosemide , Hyponatremia/chemically induced , Hypothalamic Area, Lateral/physiology , Injections, Intraventricular , Male , Potassium/blood , Potassium/urine , Random Allocation , Rats , Rats, Sprague-Dawley , Receptors, Mineralocorticoid/physiology , Renin/blood , Renin-Angiotensin System/physiology , Self Stimulation/physiology , Sodium/blood , Sodium/urine , Spironolactone/administration & dosage , Spironolactone/analogs & derivatives , Spironolactone/pharmacology
18.
Pharmacol Biochem Behav ; 93(4): 368-74, 2009 Oct.
Article in English | MEDLINE | ID: mdl-19450620

ABSTRACT

In general terms, sensitization refers to the capacity of a repetitive stimulus of fixed strength to produce a progressive increase in the magnitude of a response with each stimulation. In the addiction literature cross-sensitization is the capacity of an agent with abuse potential to sensitize a behavioral response induced by another stimulus. In the present experiments we examined the effects of morphine pretreatment on furosemide-induced saline intake and conversely sodium appetite induction on morphine-induced locomotion. In an initial experiment rats were pretreated with morphine (10 mg/kg, s.c.) or vehicle for 5 days. The rats were then sodium or sham depleted and 24 h later given a sodium appetite test. Sodium depleted rats pretreated with morphine increased saline intake compared to depleted rats initially pretreated with vehicle. In a second experiment rats that were previously depleted and repleted of sodium as compared to sham depleted animals showed enhanced locomotor activity in an open field test when challenged with morphine (1 mg/kg, s.c.). These studies demonstrate that the behavioral responses induced by sodium deficiency and morphine treatment cross-sensitize with one another and suggest that common neural substrates underlie the sensitization of behaviors associated with states induced by morphine and sodium appetite.


Subject(s)
Analgesics, Opioid/pharmacology , Appetite/drug effects , Behavior, Animal/drug effects , Morphine/pharmacology , Motor Activity/drug effects , Sodium/deficiency , Animals , Data Interpretation, Statistical , Diuretics/pharmacology , Drinking/drug effects , Eating/drug effects , Furosemide/pharmacology , Male , Rats , Rats, Sprague-Dawley
19.
Physiol Behav ; 94(5): 709-21, 2008 Aug 06.
Article in English | MEDLINE | ID: mdl-18514747

ABSTRACT

Ionic sodium, obtained from dietary sources usually in the form of sodium chloride (NaCl, common table salt) is essential to physiological function, and in humans salt is generally regarded as highly palatable. This marriage of pleasant taste and physiological utility might appear fortunate--an appealing taste helps to ensure that such a vital substance is ingested. However, the powerful mechanisms governing sodium retention and sodium balance are unfortunately best adapted for an environment in which few humans still exist. Our physiological and behavioral means for maintaining body sodium and fluid homeostasis evolved in hot climates where sources of dietary sodium were scarce. For many reasons, contemporary diets are high in salt and daily sodium intakes are excessive. High sodium consumption can have pathological consequences. Although there are a number of obstacles to limiting salt ingestion, high sodium intake, like smoking, is a modifiable behavioral risk factor for many cardiovascular diseases. This review discusses the psychobiological mechanisms that promote and maintain excessive dietary sodium intake. Of particular importance are experience-dependent processes including the sensitization of the neural systems underlying sodium appetite and the effects of sodium balance on hedonic state and mood. Accumulating evidence suggests that plasticity within the central nervous system as a result of experience with high salt intake, sodium depletion, or a chronic unresolved sodium appetite fosters enduring changes in sodium related appetitive and consummatory behaviors.


Subject(s)
Appetite/drug effects , Eating/psychology , Sodium, Dietary/pharmacology , Taste/drug effects , Animals , Appetite Regulation/physiology , Appetitive Behavior/drug effects , Eating/drug effects , Feeding Behavior/drug effects , Feeding Behavior/psychology , Humans , Hypothalamus/drug effects , Hypothalamus/physiology , Motivation , Nutritional Requirements , Rats , Reward , Taste/physiology
20.
Brain Res ; 1171: 104-10, 2007 Sep 26.
Article in English | MEDLINE | ID: mdl-17822683

ABSTRACT

Sodium appetite is associated with a form of behavioral plasticity in which animals experimentally depleted of sodium progressively increase their intake of hypertonic NaCl over several successive (on 2 to 4 occasions) depletion. The present experiment explored the nature of this plasticity by quantifying Fos immunoreactivity (Fos-ir) in structures implicated in the mediation of sodium appetite and in the signaling of reward. Rats were depleted of sodium with the diuretic furosemide three times (3F), one time (2V1F) or sham depleted (i.e., vehicle treated; 3V). Rats were given sodium appetite tests for the first two treatments. The sodium appetite test was omitted after the third treatment. Fos-ir activity was quantified in the paraventricular nucleus (PVN), subfornical organ (SFO), supraoptic nucleus (SON), nucleus accumbens (NAc) shell and core, basolateral (BLA) and central amygdala (CeA), and medial prefrontal cortex (mPFC). Animals receiving repeated sodium depletions increased sodium ingestion across initial depletions. Fos-ir activity was markedly enhanced in the SFO, BLA, and shell of the NAc of 3F rats relative to 2V1F and 3V animals. These results indicate that repeated experience with sodium depletion and ingestion affects both behavioral and neural responses to sodium. Experience with sodium depletion enhances its ingestion and may have a direct impact on central structures implicated in sodium appetite and reward signaling.


Subject(s)
Appetite/physiology , Brain/anatomy & histology , Brain/physiology , Salts , Sodium/deficiency , Analysis of Variance , Animals , Appetite/drug effects , Behavior, Animal/drug effects , Brain/drug effects , Brain Mapping , Drinking Behavior/drug effects , Furosemide/pharmacology , Male , Oncogene Proteins v-fos/metabolism , Rats , Rats, Sprague-Dawley , Sodium/urine , Sodium Potassium Chloride Symporter Inhibitors/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...